share_log

BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT

BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT

BIOVAXYS宣布计划进行私募融资
PR Newswire ·  03/23 05:05

VANCOUVER, BC, March 22, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") announces that it intends to complete a non-brokered private placement (the "Private Placement") consisting of up to 15,384,615 units ("Units") at a price of $0.065 per Unit for total gross proceeds of up to CAD$1,000,000, before deducting any offering-related expenses. Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant"). Each Warrant is exercisable for one additional Common Share at an exercise price of $0.15 for a period of 24 months.

不列颠哥伦比亚省温哥华,2024年3月22日 /PRNewswire/ — BioVaxys Technology Corp.(CSE:BIOV)(FRA:5LB)(场外交易代码:BVAXF)(“BioVaxys” 或 “公司”)宣布,它打算按价格完成一项不超过15,384,615个单位(“单位”)的非经纪私募配售(“私募配售”)在扣除任何与发行相关的费用之前,每单位0.065美元,总收益最高为1,000,000加元。每个单位由一股普通股(“普通股”)和一份完整的普通股购买权证(“认股权证”)组成。每份认股权证可额外行使一股普通股,行使价为0.15美元,为期24个月。

Closing of the private placement is conditional upon finalizing all contractual documentation and receipt of all applicable regulatory approvals and the policies of the Canadian Securities Exchange ("CSE"). All securities issued pursuant to the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance. The Company intends to use the net proceeds of the Private Placement for general working capital purposes, including, enabling the Company to fund and advance its business plans in regard to its successful recent acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX immune educating platform technology, developed by the former Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., and IMV USA ("IMV") on February 16th, 2024.The Company may pay a finder's fee related to the financing.

私募的完成前提是完成所有合同文件并获得所有适用的监管批准和加拿大证券交易所(“CSE”)的政策。所有根据私募发行的证券均受自发行之日起四个月零一天的法定持有期限。公司打算将私募的净收益用于一般营运资金用途,包括使公司能够为其最近成功收购肿瘤、传染病、抗原脱敏和其他免疫学领域的全部发现、临床前和临床开发阶段资产组合提供资金和推进其业务计划,这些资产基于加拿大前生物技术公司IMMV Inc.Immunovacc.开发的DPX免疫教育平台技术 Ine Technologies Inc. 和 IMV USA(”IMV”)将于2024年2月16日生效。公司可能会支付与融资相关的发现费。

About BioVaxys Technology Corp.

关于 BioVaxys 科技公司

BioVaxys Technology Corp. (), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and it's HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.

BioVaxys Technology Corp. () 是一家在加拿大不列颠哥伦比亚省注册的生物制药公司,是一家临床阶段的生物制药公司,致力于通过基于DPX免疫教育技术平台及其Haptenix “新抗原” 肿瘤细胞构建平台的新型免疫疗法改善患者生活,用于治疗癌症、传染病、抗原脱敏和其他免疫学领域。该公司的临床阶段产品线包括MaveropePimut-S,它正处于晚期复发难治性弥漫性大B细胞淋巴瘤(DLBCL)和耐铂性卵巢癌的二期临床开发,以及使用其专有的Haptenix'新抗原'肿瘤细胞构建平台的个性化免疫治疗疫苗,该平台即将在西班牙进入I期,用于治疗屈光晚期卵巢癌。BVX-0918该公司还利用其肿瘤免疫学专业知识,利用其个性化免疫治疗疫苗创建了独特的T淋巴细胞和其他数据集库,以利用预测算法和其他技术来识别新的可靶向肿瘤抗原。BioVaxys的普通股在CSE上市,股票代码为 “BIOV”,并在法兰克福证券交易所(FRA:5LB)和美国(场外交易代码:BVAXF)上市。欲了解更多信息,请访问并通过 X 和 LinkedIn 联系我们。

ON BEHALF OF THE BOARD

代表董事会

Signed "James Passin"
James Passin, CEO
+1 646 452 7054

签名 “詹姆斯·帕森”
首席执行官詹姆斯·帕辛先生
+1 646 452 7054

Logo -

徽标-

SOURCE BioVaxys Technology Corp.

来源 bioVaxys 科技公司

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发